Oncology Medical News about advanced NSCLC;ERCC1;poorer platinum-based treatment outcome

Become a Member Today!
Register

Most Viewed Abstracts

1. Report Shows Shift in Starting Salaries for Physicians

2. Recommendations on the use of 18F-FDG PET in oncology

3. Taxane-based combinations as adjuvant chemotherapy of early breast cancer: a meta-analysis of randomized trials

4. Gene expression signatures, clinicopathological features, and individualized therapy in breast cancer

5. Sentinel node biopsy is important in mastectomy for ductal carcinoma in situ

Your Article Summary

See Latest Articles

(Click the title below to leave the MDLinx Network and go to the Journal's Website)

Positive expression of ERCC1 predicts a poorer platinum-based treatment outcome in Chinese patients with advanced non-small-cell lung cancer
Medical Oncology, 06/08/09

Wang X et al. - In a study to determine role of excision repair cross-complementing group 1 gene (ERCC1) and ribonucleotide reductase subunit M1 (RRM1) expression in predicting response and survival in Chinese pts with advanced stage non-small cell lung cancer (NSCLC) treated with platinum-based chemotherapy, it was concluded that tumor ERCC1 expression is associated with tumor response and survival in advanced NSCLC pts treated with platinum-based regimen and may serve as a biomarker in predicting tumor response and clinical outcome in the pt population.

Methods

Formalin-fixed, paraffin-embedded biopsy tissues were retrospectively obtained from 124 advanced NSCLC pts.
Protein expression levels of ERCC1 and RRM1 were determined by immunohistochemistry (IHC).
Associations between expression of ERCC1 and RRM1 and clinic-pathologic parameters were analyzed.

Results

ERCC1 and RRM1 expression were detected in 43 (35%) and 50 (40%) of the 124 tumor samples, respectively.
Expression of ERCC1 and RRM1 was negatively associated with tumor response.
54% of pts whose tumors did not express ERCC1 had partial response (PR) vs 33% whose tumors expressed the protein.
54% pts whose tumor did not express RRM1 had PR vs 36% whose tumors express the protein.
Pts whose tumors lacked ERCC1 but not RRM1 expression had a longer median survival time than those tumors expressed ERCC1 (13.4 mos vs 9.1 mos), which is independent of other prognostic factors.